ArticleInternational journal of general medicine2026
Association of week-12 HBsAg Decline with HBsAg Clearance in Patients with Hepatitis B-Related Cirrhosis Receiving Pegylated Interferon Combined with Nucleos(T)ide Analogue Therapy: A Retrospective Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the association between the relative decline rate of HBsAg at week 12 (HBsAg R) and achieving HBsAg clearance in patients with compensated HBV-related cirrhosis. Patients and Methods: This study included 174 patients with compensated hepatitis B-related cirrhosis receiving pegylated interferon-alpha and nucleos(t)ide analogue therapy. HBsAgR was defined as (week-12 HBsAg - baseline HBsAg) / baseline HBsAg, where a more negative value indicates greater decline. To identify stable predictors, we employed the Boruta machine learning algorithm for feature selection. The association between HBsAgR and HBsAg clearance at 48 weeks was assessed using multivariable logistic regression and ROC analysis. Model stability was internally validated using Bootstrap resampling with 1,000 iterations. Results: HBsAgR was identified as a stable factor associated with HBsAg clearance. After adjustment, each one-unit increase in HBsAgR was associated with a 53% lower odds of clearance (aOR=0.47; 95% CI: 0.28-0.79), indicating that greater HBsAg decline (more negative HBsAgR) was associated with higher clearance probability. ROC analysis showed an AUC of 0.746. The optimal cutoff value of HBsAgR was -0.56585, which corresponds to a 56.6% decline in HBsAg from baseline at week 12. Patients with HBsAgR less than -0.56585 (ie, a decline greater than 56.6%) were associated with a higher probability of HBsAg clearance, yielding a sensitivity of 76.19% and specificity of 73.33%. Bootstrap validation showed minimal optimism (difference: -0.001). Conclusion: HBsAgR is strongly associated with HBsAg clearance at week 48 in patients with hepatitis B-related cirrhosis, and may serve as a useful modicification of treatment strategies for this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.